Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

875 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Long-term efficacy of reduced-intensity versus myeloablative conditioning before allogeneic haemopoietic cell transplantation in patients with acute myeloid leukaemia in first complete remission: retrospective follow-up of an open-label, randomised phase 3 trial.
Fasslrinner F, Schetelig J, Burchert A, Kramer M, Trenschel R, Hegenbart U, Stadler M, Schäfer-Eckart K, Bätzel M, Eich H, Stuschke M, Engenhart-Cabillic R, Krause M, Dreger P, Neubauer A, Ehninger G, Beelen D, Berdel WE, Siepmann T, Stelljes M, Bornhäuser M. Fasslrinner F, et al. Among authors: stadler m. Lancet Haematol. 2018 Apr;5(4):e161-e169. doi: 10.1016/S2352-3026(18)30022-X. Epub 2018 Mar 14. Lancet Haematol. 2018. PMID: 29550384 Clinical Trial.
Reduced-intensity conditioning versus standard conditioning before allogeneic haemopoietic cell transplantation in patients with acute myeloid leukaemia in first complete remission: a prospective, open-label randomised phase 3 trial.
Bornhäuser M, Kienast J, Trenschel R, Burchert A, Hegenbart U, Stadler M, Baurmann H, Schäfer-Eckart K, Holler E, Kröger N, Schmid C, Einsele H, Kiehl MG, Hiddemann W, Schwerdtfeger R, Buchholz S, Dreger P, Neubauer A, Berdel WE, Ehninger G, Beelen DW, Schetelig J, Stelljes M. Bornhäuser M, et al. Among authors: stadler m. Lancet Oncol. 2012 Oct;13(10):1035-44. doi: 10.1016/S1470-2045(12)70349-2. Epub 2012 Sep 7. Lancet Oncol. 2012. PMID: 22959335 Clinical Trial.
Outcome of patients with abnl(17p) acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation.
Middeke JM, Fang M, Cornelissen JJ, Mohr B, Appelbaum FR, Stadler M, Sanz J, Baurmann H, Bug G, Schäfer-Eckart K, Hegenbart U, Bochtler T, Röllig C, Stölzel F, Walter RB, Ehninger G, Bornhäuser M, Löwenberg B, Schetelig J. Middeke JM, et al. Among authors: stadler m. Blood. 2014 May 8;123(19):2960-7. doi: 10.1182/blood-2013-12-544957. Epub 2014 Mar 20. Blood. 2014. PMID: 24652988 Free article.
Outcome of high-risk acute myeloid leukemia after allogeneic hematopoietic cell transplantation: negative impact of abnl(17p) and -5/5q-.
Middeke JM, Beelen D, Stadler M, Göhring G, Schlegelberger B, Baurmann H, Bug G, Bellos F, Mohr B, Buchholz S, Schwerdtfeger R, Martin H, Hegenbart U, Ehninger G, Bornhäuser M, Schetelig J; Cooperative German Transplant Study Group. Middeke JM, et al. Among authors: stadler m. Blood. 2012 Sep 20;120(12):2521-8. doi: 10.1182/blood-2012-03-417972. Epub 2012 Jul 31. Blood. 2012. PMID: 22855604 Free article.
Treatment of acute myeloid leukemia or myelodysplastic syndrome relapse after allogeneic stem cell transplantation with azacitidine and donor lymphocyte infusions--a retrospective multicenter analysis from the German Cooperative Transplant Study Group.
Schroeder T, Rachlis E, Bug G, Stelljes M, Klein S, Steckel NK, Wolf D, Ringhoffer M, Czibere A, Nachtkamp K, Dienst A, Kondakci M, Stadler M, Platzbecker U, Uharek L, Luft T, Fenk R, Germing U, Bornhäuser M, Kröger N, Beelen DW, Haas R, Kobbe G. Schroeder T, et al. Among authors: stadler m. Biol Blood Marrow Transplant. 2015 Apr;21(4):653-60. doi: 10.1016/j.bbmt.2014.12.016. Epub 2014 Dec 23. Biol Blood Marrow Transplant. 2015. PMID: 25540937 Free article. Clinical Trial.
A multicenter prospective, randomized, placebo-controlled phase II/III trial for preemptive acute graft-versus-host disease therapy.
Weissinger EM, Metzger J, Schleuning M, Schmid C, Messinger D, Beutel G, Wagner-Drouet EM, Schetelig J, Baurmann H, Rank A, Stolzl F, Schäfer-Eckart K, Westphal K, Bethge W, von Harsdorf S, Bunjes DW, Heidenreich D, Klein S, Holler E, Kreipe HH, Jonigk D, Türüchanow I, Raad J, Papkalla A, von der Leyen H, Hambach L, Hamwi I, Ehrlich S, Krauter J, Stadler M, Ganser A. Weissinger EM, et al. Among authors: stadler m. Leukemia. 2021 Jun;35(6):1763-1772. doi: 10.1038/s41375-020-01059-3. Epub 2020 Oct 20. Leukemia. 2021. PMID: 33082512 Free PMC article. Clinical Trial.
Comparison Between 5-Azacytidine Treatment and Allogeneic Stem-Cell Transplantation in Elderly Patients With Advanced MDS According to Donor Availability (VidazaAllo Study).
Kröger N, Sockel K, Wolschke C, Bethge W, Schlenk RF, Wolf D, Stadler M, Kobbe G, Wulf G, Bug G, Schäfer-Eckart K, Scheid C, Nolte F, Krönke J, Stelljes M, Beelen D, Heinzelmann M, Haase D, Buchner H, Bleckert G, Giagounidis A, Platzbecker U. Kröger N, et al. Among authors: stadler m. J Clin Oncol. 2021 Oct 20;39(30):3318-3327. doi: 10.1200/JCO.20.02724. Epub 2021 Jul 20. J Clin Oncol. 2021. PMID: 34283629 Clinical Trial.
Radioimmunotherapy with yttrium-90-ibritumomab tiuxetan as part of a reduced- intensity conditioning regimen for allogeneic hematopoietic cell transplantation in patients with advanced non-Hodgkin lymphoma: results of a phase 2 study.
Bethge WA, Lange T, Meisner C, von Harsdorf S, Bornhaeuser M, Federmann B, Stadler M, Uharek L, Stelljes M, Knop S, Wulf G, Trenschel R, Vucinic V, Dittmann H, Faul C, Vogel W, Kanz L, Bunjes D. Bethge WA, et al. Among authors: stadler m. Blood. 2010 Sep 9;116(10):1795-802. doi: 10.1182/blood-2010-02-270538. Epub 2010 Jun 7. Blood. 2010. PMID: 20530284 Free article. Clinical Trial.
Allogeneic stem cell transplantation provides durable disease control in poor-risk chronic lymphocytic leukemia: long-term clinical and MRD results of the German CLL Study Group CLL3X trial.
Dreger P, Döhner H, Ritgen M, Böttcher S, Busch R, Dietrich S, Bunjes D, Cohen S, Schubert J, Hegenbart U, Beelen D, Zeis M, Stadler M, Hasenkamp J, Uharek L, Scheid C, Humpe A, Zenz T, Winkler D, Hallek M, Kneba M, Schmitz N, Stilgenbauer S; German CLL Study Group. Dreger P, et al. Among authors: stadler m. Blood. 2010 Oct 7;116(14):2438-47. doi: 10.1182/blood-2010-03-275420. Epub 2010 Jul 1. Blood. 2010. PMID: 20595516 Free article. Clinical Trial.
Early autologous stem cell transplantation for chronic lymphocytic leukemia: long-term follow-up of the German CLL Study Group CLL3 trial.
Dreger P, Döhner H, McClanahan F, Busch R, Ritgen M, Greinix H, Fink AM, Knauf W, Stadler M, Pfreundschuh M, Dührsen U, Brittinger G, Hensel M, Schetelig J, Winkler D, Bühler A, Kneba M, Schmitz N, Hallek M, Stilgenbauer S; German CLL Study Group. Dreger P, et al. Among authors: stadler m. Blood. 2012 May 24;119(21):4851-9. doi: 10.1182/blood-2011-09-378505. Epub 2012 Apr 5. Blood. 2012. PMID: 22490331 Free article. Clinical Trial.
875 results